TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07719023: A Multicenter, Randomized, Double-Blind, Placebo-Controlled and Open-Label Active-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Sponsor: Shanghai Ark Biopharmaceutical Co., Ltd. · Phase: PHASE3 · Area: IMMUNOLOGY · Target Enrollment: 263 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$15,676,800

Rescue Site Savings

+$10,336,890

Unlock Full NCT07719023 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07719023 Rescue Dossier →